查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403407

2030 年小分子免疫調節藥物市場預測：按產品、應用、最終用戶和地區進行的全球分析

Small Molecule Immunomodulators Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球小分子免疫調節劑市場規模為1,690.6億美元，預計到2030年將達到2,935.2億美元，預測期內複合年成長率為8.2%。

小分子免疫調節劑是可以調節免疫系統的小分子化合物。這些化合物在調節免疫反應、根據需要增強或抑制免疫反應方面發揮重要作用。小分子免疫調節藥物在治療多種疾病（包括自體免疫疾病、發炎疾病和某些癌症）方面具有微調免疫系統活性並提高療效的潛力，使其成為免疫療法的有吸引力的選擇。

根據美國國家多發性硬化症協會 2020 年 9 月發布的報告，全球有 280 萬人患有多發性硬化症，光是美國居住超過 100 萬人。

免疫疾病增加

免疫疾病的流行已成為小分子免疫調節藥物的重要驅動力。隨著自體免疫疾病和其他免疫疾病變得越來越普遍，對創新治療方法的需求不斷成長。小分子免疫調節劑旨在在分子層面上調節免疫反應，並因其控制這些疾病的潛力而受到重視。免疫疾病盛行率的上升是研究、開發和市場開拓的驅動力。

副作用和安全問題

小分子免疫調節劑可能與胃腸道失調、皮膚反應和免疫抑制等副作用有關。安全性問題包括可能對免疫功能的長期影響和機會性感染疾病的風險。此外，藥物交互作用和反應的個體差異也帶來了挑戰。此外，這些免疫調節劑的長期影響仍在接受審查，對潛在突發事件的擔憂進一步阻礙了市場需求。

藥物開發的進展

標靶治療、個人化醫療和新型小分子化合物等創新在調節免疫系統方面顯示出有希望的結果。這些進步不僅提高了治療效果，還有助於最大限度地減少副作用。免疫調節藥物開發的進展正在創造有利的市場開拓環境，並為透過有針對性的有效干預措施解決各種疾病和病症提供新途徑。

學名藥競爭

由於主要免疫調節劑的專利到期，小分子免疫調節劑正面臨學名藥的激烈競爭。當專利到期時，學名藥公司可以進入市場並提供更實惠的品牌藥替代品。這種日益激烈的競爭為患者提供了具有成本效益的選擇。製藥公司之間的競爭加劇可能會降低創新製藥公司的報酬率並阻礙市場擴張。

COVID-19 的影響

COVID-19的爆發對小分子免疫調節藥物市場產生了重大影響。人們越來越關注增強免疫反應和治療發炎疾病，這增加了對免疫調節劑的需求。然而，藥品供應鏈的中斷、臨床試驗的延誤和經濟的不確定性正在影響市場的成長。這次疫情凸顯了免疫調節藥物研發的重要性，但製造和分銷方面的挑戰限制了市場的擴張。總體而言，市場正在經歷持續的全球健康危機所帶來的機會和挑戰的混合影響。

在預測期內，心臟手術領域預計將是最大的。

由於其準確性和有效性，心臟手術領域預計將出現良好的成長。小分子免疫調節劑在心血管手術過程中調節免疫反應、減輕發炎反應、最佳化身體對手術的耐受性方面發揮重要作用。這可以最大限度地減少術後併發症並改善患者的整體治療效果。這種免疫調節劑的精確性和標靶性使其成為心血管手術領域有價值的輔助手段。

預計醫院和診所產業在預測期內將經歷最高的複合年成長率。

醫院和診所預計在預測期內複合年成長率最高。在醫院和診所，小分子免疫調節劑市場透過調節免疫反應在解決各種醫療狀況方面發揮著至關重要的作用。這些藥物給藥治療自體免疫疾病、癌症和發炎疾病。這些藥物有助於改善患者的預後，同時最大限度地減少與副作用相關的風險。其有效性和安全性正在推動該領域的發展。

比最大的地區

由於免疫疾病患者數量不斷增加，預計亞太地區在預測期內將佔據最大的市場佔有率。人們對這些疾病的認知不斷提高，醫療保健投資不斷增加，正在推動市場擴張。此外，該地區老年人口的成長和生活方式的改變也導致自體自體免疫疾病的迅速增加。隨著製藥公司專注於創新免疫調節藥物的開發和商業化，面對日益嚴峻的免疫挑戰，迫切需要有效的治療方法，亞太市場有望大幅成長。

複合年成長率最高的地區：

由於門診外科手術的採用率增加以及對具有成本效益的醫療保健服務的重視，預計北美在預測期內將呈現最高的複合年成長率。自體自體免疫疾病的日益普及和人口高齡化正在推動對先進免疫調節療法的需求。該地區擁有發達的醫療基礎設施，持續的研究舉措正在促進市場擴張。主要企業正在投資開發新藥，加強市場競爭形勢。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球小分子免疫調節藥物市場：依產品

  • 免疫抑制劑
    • Calcineurin抑制劑
    • 糖皮質素
    • mTOR抑制劑
  • 活化
    • 白細胞介素
    • 干擾素
  • 1-磷酸鞘氨醇 (S1P) 受體調節劑
  • Janus 激酶 (JAK) 抑制劑
  • 其他產品

第6章全球小分子免疫調節藥物市場：依應用分類

  • 胸部
  • 眼科
  • 大腸直腸
  • 心血管手術
  • 神經外科
  • 整形外科
  • 婦科
  • 其他用途

第7章全球小分子免疫調節藥物市場：依最終用戶分類

  • 醫院和診所
  • 製藥和生物技術公司
  • 研究和學術機構
  • 門診手術中心
  • 居家照護環境
  • 其他最終用戶

第8章全球小分子免疫調節藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Boston Scientific Corporation
  • Medline Industries
  • Molnlycke Health Care
  • Cardinal Health Inc
  • Owens & Minor, Inc.
  • B. Braun Melsungen AG
  • Teleflex Incorporated
  • Smith & Nephew Plc
  • Thermo Fisher Scientific Inc.
  • Halyard Health Inc
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Odyssey Therapeutics Inc
Product Code: SMRC24632

According to Stratistics MRC, the Global Small Molecule Immunomodulators Market is accounted for $169.06 billion in 2023 and is expected to reach $293.52 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Small molecule immunomodulators are compounds with low molecular weight that can regulate the immune system. These compounds play a crucial role in modulating immune responses, either enhancing or suppressing them as needed. Small molecule immunomodulators are extensively studied in the field of immunotherapy for their potential in treating various diseases, including autoimmune disorders, inflammatory conditions, and certain cancers, by fine-tuning the immune system's activity for therapeutic benefits.

According to a report published by the National Multiple Sclerosis Society in September 2020, there are 2.8 million people worldwide who have multiple sclerosis, and more than 1 million reside in the United States alone.

Market Dynamics:

Driver:

Rising incidence of immunological disorders

The escalating prevalence of immunological disorders is a key catalyst of the small molecule immunomodulators. As autoimmune diseases and other immunological disorders become more widespread, there is an increasing demand for innovative therapeutic solutions. Small molecule immunomodulators, designed to modulate the immune response at a molecular level, are gaining prominence for their potential in managing these conditions. This rising incidence of immunological disorders is thereby driving research, development, and market expansion.

Restraint:

Side effects and safety concerns

The small molecule immunomodulators may entail side effects such as gastrointestinal issues, skin reactions, and immune suppression. Safety concerns include potential long-term impacts on immune function and the risk of opportunistic infections. Additionally, drug interactions and individual variability in response pose challenges. Moreover, the long-term effects of these immunomodulators remain under scrutiny, raising concerns about potential unforeseen consequences which further hinder the market demand.

Opportunity:

Advancements in drug development

Innovations such as targeted therapies, personalized medicine, and novel small molecule compounds have shown promising results in modulating the immune system. These advancements not only enhance treatment efficacy but also contribute to minimizing adverse effects. The evolving landscape of drug development in immunomodulation creates a favourable environment for market growth, offering new avenues for addressing various diseases and disorders through precise and effective interventions.

Threat:

Generic competition

The small molecule immunomodulators witnesses robust generic competition due to the expiration of patents for key immunomodulatory drugs. As patents expire, generic pharmaceutical companies can enter the market, offering more affordable alternatives to the original branded drugs. This increased competition promotes cost-effective options for patients. This intensified competition among pharmaceutical companies, potentially leads to reduced profit margins for innovator companies thereby hampering the market expansion.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the small molecule immunomodulators Market. The increased focus on enhancing immune responses and treating inflammatory conditions has driven demand for immunomodulators. However, disruptions in the pharmaceutical supply chain, delayed clinical trials, and economic uncertainties have affected market growth. The pandemic has underscored the importance of research and development in immunomodulatory drugs, but challenges in manufacturing and distribution have tempered market expansion. Overall, the market has experienced a mixed impact with both opportunities and challenges arising from the ongoing global health crisis.

The cardiac surgery segment is expected to be the largest during the forecast period

The cardiac surgery segment is estimated to have a lucrative growth, due to its accuracy and efficacy. Small molecule immunomodulators play a crucial role in modulating the immune response during cardiac surgery, mitigating inflammatory reactions and optimizing the body's tolerance to the procedure. It minimizes postoperative complications and enhances overall patient outcomes. The precision and targeted nature of these immunomodulators makes them valuable adjuncts in the field of cardiac surgery.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to witness the highest CAGR growth during the forecast period. In hospitals and clinics, the Small Molecule Immunomodulators market plays a pivotal role in addressing diverse medical conditions by modulating immune responses. These pharmaceuticals are administered to manage autoimmune disorders, cancer, and inflammatory diseases. They contribute positive patient outcomes while minimizing risks associated with adverse reactions. Its efficacy and safety factors boost the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to escalating cases of immunological disorders. The rising awareness of these conditions, coupled with increasing healthcare investments, is fostering market expansion. Moreover, the region's growing geriatric population and changing lifestyles contribute to the surge in autoimmune diseases. As pharmaceutical companies focus on developing and commercializing innovative immunomodulatory drugs, the Asia-Pacific market is poised for significant advancement, driven by the pressing need for effective treatments in the face of rising immunological challenges.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increased adoption of outpatient surgical procedures and the growing emphasis on cost-effective healthcare services. Increased prevalence of autoimmune diseases and a rising aging population are driving demand for advanced immunomodulatory therapies. The region's well-established healthcare infrastructure and ongoing research initiatives contribute to market expansion. Key players are investing in novel drug development, bolstering the market's competitive landscape.

Key players in the market:

Some of the key players profiled in the Small Molecule Immunomodulators Market include Boston Scientific Corporation, Medline Industries, Molnlycke Health Care, Cardinal Health Inc, Owens & Minor, Inc., B. Braun Melsungen AG, Teleflex Incorporated, Smith & Nephew Plc, Thermo Fisher Scientific Inc., Halyard Health Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Novartis AG and Odyssey Therapeutics Inc.

Key Developments:

In December 2022, Medline Industries, as part of the European Commission's rescEU program, donated 59 pallets containing 14 tons of medical supplies to Ukraine. The contribution included essential items like delivery kits, oxygen therapy equipment, scrub suits, and scalpels & sutures, aiding healthcare efforts in the country.

In October 2022, Odyssey Therapeutics Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.

Products Covered:

  • Immunosuppressants
  • Immunostimulants
  • Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • Janus Kinase (JAK) Inhibitors
  • Other Products

Applications Covered:

  • Thoracic
  • Ophthalmology
  • Colorectal
  • Cardiac Surgery
  • Neurosurgery
  • Orthopedic
  • Gynecology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Immunomodulators Market, By Product

  • 5.1 Introduction
  • 5.2 Immunosuppressants
    • 5.2.1 Calcineurin Inhibitors
    • 5.2.2 Glucocorticoids
    • 5.2.3 mTOR Inhibitors
  • 5.3 Immunostimulants
    • 5.3.1 Interleukins
    • 5.3.2 Interferons
  • 5.4 Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • 5.5 Janus Kinase (JAK) Inhibitors
  • 5.6 Other Products

6 Global Small Molecule Immunomodulators Market, By Application

  • 6.1 Introduction
  • 6.2 Thoracic
  • 6.3 Ophthalmology
  • 6.4 Colorectal
  • 6.5 Cardiac Surgery
  • 6.6 Neurosurgery
  • 6.7 Orthopedic
  • 6.8 Gynecology
  • 6.9 Other Applications

7 Global Small Molecule Immunomodulators Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals & Clinics
  • 7.3 Pharmaceutical & Biotechnology Companies
  • 7.4 Research & Academic Institutes
  • 7.5 Ambulatory Surgical Centers
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Small Molecule Immunomodulators Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Boston Scientific Corporation
  • 10.2 Medline Industries
  • 10.3 Molnlycke Health Care
  • 10.4 Cardinal Health Inc
  • 10.5 Owens & Minor, Inc.
  • 10.6 B. Braun Melsungen AG
  • 10.7 Teleflex Incorporated
  • 10.8 Smith & Nephew Plc
  • 10.9 Thermo Fisher Scientific Inc.
  • 10.10 Halyard Health Inc
  • 10.11 Eli Lilly and Company
  • 10.12 Teva Pharmaceutical Industries Limited
  • 10.13 Novartis AG
  • 10.14 Odyssey Therapeutics Inc

List of Tables

  • Table 1 Global Small Molecule Immunomodulators Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Small Molecule Immunomodulators Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Small Molecule Immunomodulators Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 4 Global Small Molecule Immunomodulators Market Outlook, By Calcineurin Inhibitors (2021-2030) ($MN)
  • Table 5 Global Small Molecule Immunomodulators Market Outlook, By Glucocorticoids (2021-2030) ($MN)
  • Table 6 Global Small Molecule Immunomodulators Market Outlook, By mTOR Inhibitors (2021-2030) ($MN)
  • Table 7 Global Small Molecule Immunomodulators Market Outlook, By Immunostimulants (2021-2030) ($MN)
  • Table 8 Global Small Molecule Immunomodulators Market Outlook, By Interleukins (2021-2030) ($MN)
  • Table 9 Global Small Molecule Immunomodulators Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 10 Global Small Molecule Immunomodulators Market Outlook, By Sphingosine-1-Phosphate (S1P) Receptor Modulators (2021-2030) ($MN)
  • Table 11 Global Small Molecule Immunomodulators Market Outlook, By Janus Kinase (JAK) Inhibitors (2021-2030) ($MN)
  • Table 12 Global Small Molecule Immunomodulators Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 13 Global Small Molecule Immunomodulators Market Outlook, By Application (2021-2030) ($MN)
  • Table 14 Global Small Molecule Immunomodulators Market Outlook, By Thoracic (2021-2030) ($MN)
  • Table 15 Global Small Molecule Immunomodulators Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 16 Global Small Molecule Immunomodulators Market Outlook, By Colorectal (2021-2030) ($MN)
  • Table 17 Global Small Molecule Immunomodulators Market Outlook, By Cardiac Surgery (2021-2030) ($MN)
  • Table 18 Global Small Molecule Immunomodulators Market Outlook, By Neurosurgery (2021-2030) ($MN)
  • Table 19 Global Small Molecule Immunomodulators Market Outlook, By Orthopedic (2021-2030) ($MN)
  • Table 20 Global Small Molecule Immunomodulators Market Outlook, By Gynecology (2021-2030) ($MN)
  • Table 21 Global Small Molecule Immunomodulators Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 Global Small Molecule Immunomodulators Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Small Molecule Immunomodulators Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 24 Global Small Molecule Immunomodulators Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 25 Global Small Molecule Immunomodulators Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 26 Global Small Molecule Immunomodulators Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 27 Global Small Molecule Immunomodulators Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 28 Global Small Molecule Immunomodulators Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.